• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention relates to medicine, more specifically to methods for the production of drugs, drugs. The purpose of the invention is to simplify the technological process. For this, a portion of the calf thymus is crushed to a slurry, pyrogen-free bidistilled water is added to it, and high molecular weight components are precipitated in the flow heater for 10 minutes at. Then the slurry is cooled and centrifuged. Pyrogen-free water is added to the supernatant for continuous ultrafiltration. Ultrafiltrate is subjected to electrodialysis for 2 hours at a voltage of 12 V, maximum current strength of AO A. The extract yield is 1.6-1.54%., §
    公开号:SU1442064A3
    申请号:SU843798785
    申请日:1984-10-04
    公开日:1988-11-30
    发明作者:Оэртли Роберт
    申请人:Золько Базель Аг, (Фирма)；
    IPC主号:
    专利说明:

    4 4 ;:
    Yu
    about o: 4
     cm
    This invention relates to medicine, in particular to methods for the preparation of medicaments.
    The goal is to simplify the process.
    Example 1.5 kg of thymus calf, freed from adipose tissue and stored at a temperature that was crushed in meters to a slurry. 5 l of pyrogen-free, bi-distilled water was added to the slurry and high molecular weight components were precipitated in a flow heater for 10 minutes at 80 ° C. After that, the mush is cooled and centrifuged. For the continuous ultrafiltration, another 10 liters of pyrogen-free water is added to the supernatant (the membrane surface is 2.5 m PM-10 Romon HF system 1/35). The ultrafine mixture, diluted to a volume of 1 l, is subjected to electrodialysis at the full surface of the membrane 444 cm for 2 h at a constant temperature, voltage 12 V, maximum current 40 A. The extract yield is 58 g (1.16%).
    Example 2. 250 kg of fresh spleens of healthy calves (adipose tissue removed) “Frozen chunks were homogenized in a whey top for meat. The resulting slurry was heated with 250 liters of apiogenous water in a continuous heater (tube length 20 m) for 5 minutes to, then cooled in a continuous cooler for 6 minutes to. Centrifuged. The supernatant was subjected to i ultrafiltration continuously with the addition of 900 liters of pyrogen-free water (m.v., 000 daltons). The ultrafiltrate was evaporated in a circulation evaporator and then sterilized. The spleen concentrate was electrodialized in portions of 5 l at a membrane surface of 1776 cm, a constant temperature of 37 ° C, a constant voltage of 50 V, and a maximum current of 45 A for 3 hours. The process was carried out in a closed system. The yield of 3850 g (1.54%).
    EXAMPLE 3 Epithelial cells of calf embryonic points (FKNE) are cultured in mobile bottles up to 850 ml with minimal essential medium and 7% fetal calf serum. Shortly before the formation of a closed cell cover, the latter is flushed with a cooking solution.
    0
    five
    0
    five
    0
    five
    0
    five
    0
    five
    salts (pH 7.2) and water released from motile bottles with ethylenediaminetetraacetate as well as a rubber scraper are placed in 4 liters of bi-distilled pyrogen-free water. FKNE cells (410 (ml) were dissolved and crushed into 100 ml portions by ultrasound (Soniprep 150: amplitude 4, medium frequency for 1 min. FKNE cell mass is heated from 4 l of water in a flow heater to a temperature of 80 ° C and cooled after 10 min to a temperature of 10 ° C. Denatured proteins and other insoluble cellular substances are separated by centrifuging in a Sorvall centrifuge with a flow rotor TZ-28 (20,000 rpm, processing time 10 min.) Then the supernatant is continuously subjected to ultrafiltration with 8 liters of bid and apyrogen oh water (border MW 10,000).
    The ultrafiltrate is concentrated to 500 ml and subjected to electrodialysis. Yield 55 mg per 100 ml of culture (0.67%).
    PRI me R 4. Serum calf.
    To 6 liters of fresh calf blood serum, 3 liters of pyrogen-free water are supplied. This suspension is heated in a flow heater to a temperature of 75 ° C, kept for 5 minutes at the same temperature and then cooled in a similar pipe system to 4 ° C. The precipitates are separated by centrifugation. The 5.5 l supernatant is continuously subjected to ultrafiltration by injecting 15 l of pyrogen-free water (mv 10,000 dalton). After a significant removal of salts using electrodialysis, a sterile and pyrogen-free solution is obtained. This low molecular weight serum extract contributes to the normalization of polymerization in fibroblasts that are reversibly damaged in culture,
    PRI me R 5 Fresh blood of the calf,
    5 l
    sew water in
    fresh calf blood from a 5 l pyrogen free flow heater to temperature b (,) C. After 3 min of constant temperature, the suspension is cooled in a flow cooler to 4 ° C and the precipitated products are removed by centrifugation. The 6 l supernatant is subjected to continuous ultrafiltration by feeding 18 l of pyrogen-free water (mv 10,000 daltons). After significant removal of salts by electrodialysis, a sterile pyrogen-free solution is obtained. The thus obtained low molecular weight extract from calf blood contributes to the normalization of proliferation in fibroblasts reversibly damaged in culture.
    PRI me R 6. Defibrinated calf blood.
    5.1 kg of defibrated calf blood is heated with 5 liters of pyrogen-free water in a flow heater to a temperature of 80 ° C and kept for 5 minutes at the same high temperature. The slurry is then cooled in a flow cooler to a temperature of 4 ° C and the precipitated substances of the centrifugation aid are removed. The 7 l supernatant is continuously subjected to ultrafiltration by feeding 18 l of pyrogen-free water (mv; 10 PSO Dalton). After performing electrodialysis, a salt-depleted, sterile and pyrogen-free concentrated solution is obtained. The solution contributes to the normalization of polyportation in fibroblasts that are reversibly damaged in culture.
    Example. Spinal Calf.
    5 kg of the brain is isolated from the vertebra bones of a freshly calfted healthy calf and heated with 5 liters of pyrogen-free water in a flow heater to a temperature of 80 ° C and extracted for 5 minutes at a constant temperature. Then the mush is cooled in
    s
    1/3 of the volume, as supernatant, is used directly for the next step. 3 l is subjected to lyrafiltration with 9 l of pyrogen-free water (mv: dalton) Salt ions are extracted from the concentrate by electrodialysis. The salt-depleted solution was sterile and pyrogen-free. It contributed to the normalization of proliferation in fibroblasts, reversibly damaged
    flow cooler to temperature After centrifugation
    In culture and
    increase activity
    limiting deoxy nitrosferase in bone marrow cells.
    Example8. Brain of the femur.
    The slurry from 3.5 kg of brains and from 30kg of the femoral bones of freshly ground calves is heated with 5 liters of pyrogen-free water in a flow heater
    0 to temperature. The resulting suspension is incubated for 5 minutes After cooling in a flow cooler, the frozen fat is separated from the remaining solution. After centrifuging a defatted solution, the supernatant fluid with a volume of 5 liters is continuously subjected to ultrafiltration by feeding 15 liters of pyrogen-free water (mw 10,000 daltons). Salt ions are extracted from the concentrated preparation by means of electrolysis. The salt-depleted solution is sterile and pyrogen-free. The solution contributes to the normalization of proliferation in fibroblasts reversibly damaged in culture and an increase in the activity of limiting deoxy citransferase. EXAMPLE 9. Sheep placenta — 4.700 kg of gruel from freshly frozen placenta strongly frozen cushions of fresh sheep’s placenta is heated with 5 liters of pyrogen-free water in a flow heater to a temperature of 80 ° C and held for 5 minutes during circulation.
    35
    After cooling to 4 ° C
    40
    the precipitated substances are separated by centrifugation and the 7 l supernatant liquid is subjected to ultrafiltration continuously while feeding 10 l of pyrogen-free water (mv 10,000 daltons). The depleted solution obtained by electrodialysis was sterile and pyrogen-free. The solution was able to normalize proliferation in fibroblasts reversibly damaged in culture.
    PRI me R 10. Thymocytes. 10 kg of fresh organs of the goitre gland of the calf are ground with a 10 l solution of sodium chloride (pH 7.2) with phosphate buffer properties in a finely sieve mesh rubber stopper. As a consequence, from the tissues of the organs are separated
    50
    THYMOCYTES, remaining tissue is discarded. Then the thymocytes are washed twice with a solution of sodium chloride with phosphate buffering properties and then placed in 10 liters of bidistilled, pyrogen-free water. (1810 cells / ml). Thymocytes are dissolved and crushed with 100 ml portions of ultrasound (Soniprep 150: Amplitude 4, medium frequency) for 1 min. A slurry of thymocytes is heated with 10 liters of bidistilled pyrogen-free water in a flow-through heater to a temperature and after 10 minutes is cooled again to a temperature. Denatured proteins and other insoluble cellular substances are separated by centrifuging in a Sorvall centrifuge with a TZ-28 flow-through rotor (20,000 rpm, processing time 10 minutes). Then, the supernatant is continuously subjected to ultrafiltration with another 20 liters of bidistilled water, free of pyrogens (Dissolution limit, mp 710,000). The ultrafiltrate is concentrated to 2,000 ml and subjected to electrodialysis. A product containing peptides exhibits growth stimulating activity in CO exposed to damaged fibroblasts.
    Example 11. Culture of fibroblasts.
    Human skin fibroblasts (cell line CCL-1222) are cultured in rotating bottles of 850 ml with RPMI medium and 10% of the intrauterine body of the pharynx. The media is separated from the bound layer of cells and the cell layer is blended twice with sodium chloride solution having an acidity pH of 7.2.
    The cells are separated with a rubber gate from the bottle walls and placed in 0.5 ml of water per square centimeter, just 4 liters of water. Portions in
    U42064
    five
    0
    100 ml of still intact cells are closed and crushed for 1.5 minutes with ultrasound (Soniprep-150, amplitude 4, medium frequency).
    The slurry of cells is rapidly heated in the next 4 liters of water to 90 ° C and after 3 minutes it is cooled again to 4 ° C. The denatured proteins and cell fragments are separated using a Sorvall-centrifuge with a rotor TC-28 (20,000 rpm, time 10 minutes ). Ultrafiltered standpile liquid (the maximum value of mV 10000) is up to 500 ml. Some of the salts are removed by electrodialysis. The cell extract containing a small amount of salts is not pyrogenetic and, with reversible damaged fibroblasts, causes rapid proliferation normalization.
    权利要求:
    Claims (2)
    [1]
    1. A method of obtaining an extract that has an immunomodulatory effect from an animal by homogenizing the raw material, heating the homogenate and cooling it, precipitating the supernatant and subsequently removing the ballast proteins by ultrafiltration
    and separation of salts, characterized in that, in order to simplify the process, proteins with a molecular weight above 10,000 Dalton are removed, and the separation of salts is carried out by electrodialysis at 30-40 ° C.
    [2]
    2. Method POP1, characterized in that cell cultures are used as syQr cells, the homogenization of which is carried out with ultrasound.
    five
    0
    five
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1442064A3|1988-11-30|Method of producing extract possessing immunomodulating action from animal raw material
    US4420339A|1983-12-13|Collagen fibers for use in medical treatments
    HU218891B|2000-12-28|Method for producing tissue graft and injectable tissue graft
    CN104220586B|2017-05-17|Method for extracting collagen using ultrasonic waves, and apparatus therefor
    CN1557466A|2004-12-29|Marrow peptide preparation and its preparing process
    CN107412861B|2021-08-06|Bone repair gel of recombinant collagen compounded with chondroitin sulfate and polyethylene glycol
    EP0573668B1|1998-03-11|Bone reinforcing factor, and food and drink containing said factor
    JP3092874B2|2000-09-25|Whey-derived osteoblast-proliferating and bone-enhancing fraction and bone-enhanced food, feed, and pharmaceuticals containing the fraction
    WO2019072219A1|2019-04-18|Method for preparing protein peptide based on connective tissue and prepared protein peptide and use thereof
    JP3604159B2|2004-12-22|Whey-derived osteoblast proliferation-promoting and bone-strengthening factor and bone-strengthened food, medicine and feed containing the factor
    CN102920994B|2013-11-06|Pharmaceutical composition containing animal bone polypeptide
    CN107550933A|2018-01-09|A kind of excretion bluk recombination collagenous biological support of targeted release function and its production and use
    CN112410392A|2021-02-26|Extraction method and application of type I collagen
    RU2295963C1|2007-03-27|Method for producing immunostimulator
    RU2673802C1|2018-11-30|Method of manufacture of sterile pharmaceutical substance
    KR20150102865A|2015-09-08|Biocompatible Collagen and Methods for Preparing the Same
    RU2562581C1|2015-09-10|Method of producing biologically active agent from sea cucumber, having general tonic and immunomodulating properties
    SU1158201A1|1985-05-30|Method of obtaining stimulator from mammalia spleen
    RU2311167C2|2007-11-27|Bioimplant for compensation of defects of mineralized tissues and a method for preparation thereof
    KR20180028229A|2018-03-16|The Method of High-yield and High-purity Manufacturing of Allo-collagen Composition Extracted From Human origin
    RU1417244C|1994-06-30|Method of preparing of substance recovering prostate gland function
    JP3155746B1|2001-04-16|Method for producing type II collagen
    RU2720800C1|2020-05-13|Agent for cattle, having anti-inflammatory, regenerative, immunomodulating, detoxification, adaptogenic activity and able to regulate metabolism
    RU2149006C1|2000-05-20|Method for producing immunomodulator agents
    CN112314829A|2021-02-05|Giant salamander collagen peptide solid beverage and preparation method thereof
    同族专利:
    公开号 | 公开日
    KR910009342B1|1991-11-12|
    ZA847349B|1985-04-24|
    ES536510A0|1985-07-01|
    US4576696A|1986-03-18|
    EP0140134A2|1985-05-08|
    JPS60214738A|1985-10-28|
    JPH0374647B2|1991-11-27|
    AU3369384A|1985-04-18|
    AU568265B2|1987-12-17|
    PL249851A1|1985-05-21|
    ES8506196A1|1985-07-01|
    EP0140134A3|1988-03-23|
    EP0140134B1|1990-06-06|
    CA1230553A|1987-12-22|
    KR850002959A|1985-05-28|
    PL145552B1|1988-09-30|
    DE3482403D1|1990-07-12|
    AT53297T|1990-06-15|
    IN161706B|1988-01-16|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    LT4102B|1995-02-03|1997-01-27|Nikolaenko Alexandr N|Biologically active immunomodulating material, process for preparing thereof, pharmaceutical preparation for the human and animals physiological state conditioning|
    MD839G2|1992-07-21|1998-05-31|Alexandr Nicolaenco|Biologically active agent having immunomodulating properties, method for its obtaining, preparation based on it and method for normalization of human and animal organism physiological state|US3799806A|1972-04-20|1974-03-26|Danske Sukkerfab|Process for the purification and clarification of sugar juices,involving ultrafiltration|
    DE2325196C2|1973-05-18|1982-09-23|Böttger GmbH Pharmazeutische und Kosmetische Präparate, 1000 Berlin|Process for the production of a protein-free extract from hemolyzed blood|
    JPS5221570B2|1973-08-30|1977-06-11|
    SU559954A1|1974-09-09|1977-05-30|Московский научно-исследовательский онкологический институт им.П.А.Герцена|The method of obtaining the extracellular environment|
    DE2624373C2|1976-05-31|1983-02-03|Arnold Dr. 8782 Karlstadt Seufert|Process for the production of sterile filtered cryoprecipitate with an enrichment of factor VIII|
    FR2439205B3|1978-10-16|1981-08-14|Pabst Brewing Co|
    FR2487197A2|1979-05-11|1982-01-29|Thomas Andre|Extraction of glyco:proteins and muco:polysaccharide - by macerating animal tissue in a slightly alkaline buffer|IT1209955B|1985-05-03|1989-08-30|Serono Ist Farm|TREATMENT OF PARASITIC DISEASES|
    JPH0363348B2|1985-05-09|1991-09-30|Teijin Ltd|
    AT392003B|1988-01-13|1991-01-10|Broschek G Chem Prod Gebro|METHOD FOR PRODUCING A PARTICULARLY FOR Wounds Healing Or For Treatment In Geriatrics, Active Ingredients From Mammalian Blood By PAPAINE HYDROLYSIS AND A PREPARATION CONTAINING SUCH AN ACTIVE SUBSTANCE|
    US5055296A|1988-08-04|1991-10-08|Wagle Sudhakar S|Method of treating chronic fatigue syndrome|
    US5334395A|1988-08-04|1994-08-02|Kremers-Urban Company|Method of treating an epstein-barr viral infection|
    US5284664A|1988-08-04|1994-02-08|Kremers-Urban Company|Method of treating the symptoms of Alzheimer's disease|
    US20020031563A1|1992-09-30|2002-03-14|Hodge Thomas W.|Method of inhibiting tumor necrosis factor|
    DE19622422A1|1996-06-04|1997-12-11|Sanorell Pharma Gmbh & Co|Storage-stable pharmaceutical composition with immunomodulating and anti-inflammatory properties and a process for its production|
    DE19624476C2|1996-06-19|2001-01-04|Randolph Riemschneider|Water soluble organ extracts with improved biochemical efficiency, process for their preparation and their use|
    IL131096A|1999-07-26|2004-09-27|Can Fite Technologies Ltd|Method for preparing a composition derived from muscle tissue|
    US6284115B1|1999-09-21|2001-09-04|Agilent Technologies, Inc.|In-line flow through micro-dialysis apparatus and method for high performance liquid phase separations|
    US7243477B2|2003-03-04|2007-07-17|Diaperoos, Llc|Packaging diaper with deceptive size including vacuum-sealing|
    US20050015052A1|2003-07-17|2005-01-20|Michelle Klippen|Compression packed absorbent article|
    US20060051347A1|2004-09-09|2006-03-09|Winter Charles M|Process for concentration of antibodies and therapeutic products thereof|
    DE102004047262A1|2004-09-24|2006-04-06|Ipss International Pharmaceutical Strategies & Solutions|A pharmaceutical composition comprising blood products and their use as injection or infusion agents for the prophylaxis and treatment of immune system defects in humans|
    US20060067942A1|2004-09-24|2006-03-30|Salama Zoser B|Pharmaceutical agent comprising amino acids, peptides, proteins and/or fractions and fragments thereof and the use of same in the prophylaxis and treatment of immune system deficiency in humans and animals|
    WO2006032269A2|2004-09-24|2006-03-30|Salama Zoser B|Pharmaceutical product containing blood constituents and or kda, and the use of the same for the prophylaxis and treatment of defects of the immune system|
    EP1640012A1|2004-09-24|2006-03-29|Salama, Zoser B. nat.rer.Dr.|Pharmaceuticals agents comprising blood components10 kDa and their use for prophylaxis and treatment of defects of the immune system|
    CN103636737B|2013-10-24|2016-05-11|杨公明|A kind of Goat Placenta and amniotic fluid on-site collection and fresh-keeping method|
    CN106727711A|2016-12-09|2017-05-31|深圳市昌隽生物科技有限公司|A kind of quality standard of application and sheep embryo extract of the nanometer technology in sheep embryo extracts|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    CH541383|1983-10-05|
    [返回顶部]